SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-21			5-day change	1st Jan Change
10.57 ^CNY	-0.47%		-0.94%	+4.65%

01-13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
12-26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT

Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation

Published on 06/05/2025 at 02:22 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

01-13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
12-26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT
12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
11-04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
25-10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
25-10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
25-10-13	Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate	MT
25-09-23	Shyndec Pharmaceutical's Subsidiary Gets Nod to Add Specification to Vitamin B6 Injection	MT
25-09-18	Shyndec Pharma's Enalapril Maleate Tablets Passes Regulator's Consistency Evaluation	MT
25-09-17	Shyndec Pharmaceutical Gets Registration Certification for Penehyclidine Hydrochloride Injection	MT
25-09-01	Shyndec Pharma Obtains Drug Registration for Chest Pain Drug	MT
25-08-29	Shanghai Shyndec Pharmaceutical H1 net profit down 6.5% Y/Y	RE
25-08-08	Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride	MT
25-07-29	Shyndec Pharmaceutical's Subsidiaries Get Registration Certificates for Two Drugs	MT
25-07-18	Shyndec Pharmaceutical's H1 Profit Slips 7%, Total Revenue Drops 18%	MT
25-07-17	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-17	Shanghai Shyndec Pharmaceutical prelim H1 net profit down 6.5% Y/Y	RE
25-07-01	Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	MT
25-06-05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT
25-06-05	Shyndec Pharma Gets Registration Certificate for Hypertension Drug	MT
25-05-29	Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	MT
25-05-14	Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	MT
25-04-28	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

03-27 - Q4 2025 Earnings Release

More about the company